中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月3日星期四
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (26): 92-95    
  肿瘤医学 本期目录 | 过刊浏览 | 高级检索 |
骨髓来源抑制性细胞在上皮性卵巢癌中的临床意义
王 婷1 黄 龙2 卢志勇3 涂新飞3 万宇杰3
1.江西省人民医院肿瘤科,江西南昌 330006;
2.南昌大学第二附属医院肿瘤科,江西南昌 330006;
3.南昌市南昌县人民医院肿瘤科,江西南昌 330299
Clinical significance of myeloid-derived suppressor cells on epithelial ovarian cancer
 
WANG Ting1 HUANG Long2 LU Zhiyong3 TU Xinfei3 WAN Yujie3
1. Department of Oncology, Jiangxi Provincial People′s Hospital, Jiangxi Province, Nanchang 330006, China;
2. Department of Oncology,the Second Affiliated Hospital of Nanchang University,Jiangxi Province,Nanchang 330006,China; 
3. Department of Oncology, Nanchang County People′s Hospital, Jiangxi Province, Nanchang 330299, China
全文: PDF (536 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 
目的 观察骨髓来源抑制性细胞(MDSCs)在上皮性卵巢癌中的临床意义。 方法 选取2019年1月至2021年1月江西省人民医院收治的203 例上皮性卵巢癌患者作为研究组,115 例健康志愿者作为对照组,取两组患者外周静脉血5 ml 并用流式细胞仪检测以CD33+HLA-DR-/low 为表达特征的MDSCs 表达水平; 研究组患者根据预后结局分为预后良好组(162 例)和预后不良组(41 例),比较两组患者的CD33+HLA-DR-/low MDSCs 表达水平并采用受试者工作特征(ROC)曲线分析CD33+HLA-DR-/low MDSCs 表达水平用于判断上皮性卵巢癌预后的临床价值;结合研究组患者年龄、肿瘤分期、肿瘤大小、分化程度、病理类型信息,分析MDSCs 表达水平与上皮性卵巢癌临床指标及预后的相关性。 结果 研究组患者的CD33+HLA-DR-/low MDSCs 表达水平高于对照组, 差异有统计学意义(P<0.05);预后不良组患者的CD33+HLA-DR-/low MDSCs 表达水平高于预后良好组,差异有统计学意义(P<0.05)。CD33+HLA-DR-/lowMDSCs 表达水平用于判断上皮性卵巢癌预后的曲线下面积(AUC)为0.713(95%CI=0.646~0.775),特异度为53.70%,灵敏度为82.93%;CD33+HLA-DR-/low MDSCs 表达水平与患者年龄、肿瘤大小、病理类型无相关性(P>0.05),与肿瘤分期呈正相关(r=0.458,P<0.05),与分化程度呈负相关(r=-0.342,P<0.05)。 结论 MDSCs 在上皮性卵巢癌患者中有较高表达水平,与患者肿瘤分期、分化程度密切相关,能用于早期预后评估,以指导临床诊治。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 骨髓来源抑制性细胞CD33+HLA-DR-/lowMDSCs上皮性卵巢癌免疫抑制临床诊断预后评估    
Abstract
 Objective To observe the clinical significance of myeloid-derived suppressor cells (MDSCs) on epithelial ovarian cancer. Methods A total of 203 patients with epithelial ovarian cancer admitted to Jiangxi Provincial People′s Hospital from January 2019 to January 2021 were selected as the study group, and 115 healthy volunteers were selected as the control group. 5 ml peripheral venous blood of the two groups was collected and the expression level of MDSCs characterized by CD33+HLA-DR-/low was detected by flow cytometry. The patients in the study group were divided into a good prognosis group(162 cases)and a poor prognosis group(41 cases)according to the prognostic outcome.The expression levels of CD33+HLA-DR-/low MDSCs were compared between the two groups, and the clinical value of CD33+HLA-DR-/low MDSCs expression in predicting the prognosis of epithelial ovarian cancer was analyzed by receiver operating characteristic(ROC) curve. The correlation between the expression level of MDSCs and clinical indicators and prognosis of epithelial ovarian cancer was analyzed based on the age, tumor stage, tumor size, differentiation degree and pathological type of the patients in the study group. Results The expression level of CD33+HLA-DR-/low MDSCs in the study group was higher than that in the control group, the difference was statistically significant (P<0.05). The expression level of CD33+HLA-DR -/low MDSCs was higher in poor prognosis group than that in good prognosis group, the difference was statistically significant(P<0.05).The area under the curve (AUC), specificity and sensitivity of expression level of CD33+HLA-DR-/low MDSCs were 0.713 (95%CI=0.646-0.775), 53.70% and 82.93% in judging the prognosis of epithelial ovarian cancer. The expression level of CD33 +HLA-DR -/low MDSCs had no correlation with age, tumor size and pathological type of patients (P>0.05), but was positively correlated with tumor stage (r=0.458, P<0.05) and was negatively correlated with the degree of differentiation(r=-0.342, P<0.05). Conclusion MDSCs can have a high expression level in patients with epithelial ovarian cancer, which is closely related to the tumor stage and differentiation degree of patients, and can be used for early prognosis evaluation to guide clinical diagnosis and treatment.
Key wordsMyeloid-derived suppressor cells;CD33+HLA-DR-/lowMDSCs;Epithelial ovarian cancer;Immunosuppression;Clinical diagnosis    Prognosis evaluation
    
基金资助:
江西省卫生计生委科技计划项目(20184039)。
作者简介: 王婷(1976-),女,江西新余人,硕士,副主任医师,研究方向:肿瘤学。
引用本文:   
王 婷;黄 龙; 卢志勇;涂新飞;万宇杰. 骨髓来源抑制性细胞在上皮性卵巢癌中的临床意义[J]. 中国当代医药, 2022, 29(26): 92-95.
WANG Ting1 HUANG Long2 LU Zhiyong3 TU Xinfei3 WAN Yujie3. Clinical significance of myeloid-derived suppressor cells on epithelial ovarian cancer. 中国当代医药, 2022, 29(26): 92-95.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I26/92
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载